Spectral AI, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 14, 2026, announcing the receipt of regulatory authorization for its DeepView System. The company reported that the U.S. Food and Drug Administration (FDA) granted a De Novo classification to the device on May 21, 2026. This classification authorizes the company to commence commercial sales in the United States.
The filing includes an Investor Presentation dated September 14, 2026, which details the company’s current status and commercial strategy. According to the presentation, Spectral AI has a 13-year track record supported by over $250 million in non-dilutive government funding. The DeepView System is described as a single platform designed to support multiple indications, utilizing multispectral imaging combined with proprietary artificial intelligence to predict wound healing potential.
The company stated that the initial procurement of its systems is subsidized under a contract with the Biomedical Advanced Research and Development Authority (BARDA). An initial 30 DeepView systems are planned for deployment at U.S. burn and trauma centers. Spectral AI also noted that it has a contracted revenue base of $150 million from a Project BioShield contract with BARDA, with $86.6 million committed to date.
The filing outlines the company’s financial position as of June 30, 2026, reporting cash of $14.0 million and total assets of $19.4 million. For the first half of 2026, revenue was reported at $7.5 million, with operating expenses of $9.4 million resulting in an operating loss of $6.3 million. The company indicated that revenue tracked the development program that delivered the FDA authorization, which is now complete.
Spectral AI plans to use the proceeds from its BARDA contract to fund a commercial ramp, including building a sales team and device inventory. The company also intends to expand its international footprint, supported by United Kingdom Conformity Assessed (UKCA) marking obtained in February 2024, and is evaluating opportunities in Australia and Gulf Cooperation Countries.
